AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH
    1.
    发明公开
    AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH 审中-公开
    手段预防传染病/治疗由角质细胞所产生OUT

    公开(公告)号:EP1844778A1

    公开(公告)日:2007-10-17

    申请号:EP06712779.5

    申请日:2006-02-01

    摘要: The present invention relates to an agent for the prevention/therapy of a disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by General Formula (1):

    wherein A represents a group selected from groups of the following formulas:

    X represents CH or N;
    Y represents CH 2 or C=O;
    Z represents CH or N;
    R 1 represents an alkoxy group;
    R 2 and R 3 each independently represent an alkyl group;
    R 4 represents an alkyl group, and a group of the following formula:

    R 5 each independently represent an alkoxy group or an alkylthio group;
    m represents an integer from 1 to 3;
    n represents an integer of 1 or 2; and
    o represents an integer of 1 or 2,
    or a salt thereof, or a solvate of the compound or the salt.

    摘要翻译: 本发明涉及一种用于由角质形成细胞生长,其包含作为活性成分引起的疾病的预防/治疗的药剂,化合物由通式(1):worin甲darstellt从基的下式中选择的基团 :X CH darstellt或N; ÿdarstellt CH 2或C = O; Z表示CH或N; 的R 1个darstellt在烷氧基; R 2和R 3各自独立地表示在烷基; ,R 4 darstellt烷基,以及一组下式:R 5表示unabhängig到烷氧基或在烷硫基; 从1到3的米darstellt整数; Ñdarstellt上的1或2整数; 和邻darstellt到的1或2,或它们的盐,或所述化合物或盐的溶剂化物的整数。

    VASCULAR WALL-SELECTIVE ACAT INHIBITOR
    4.
    发明公开
    VASCULAR WALL-SELECTIVE ACAT INHIBITOR 审中-公开
    血管壁选择性ACAT抑制剂

    公开(公告)号:EP1431294A1

    公开(公告)日:2004-06-23

    申请号:EP02760658.1

    申请日:2002-08-19

    申请人: Kowa Company Ltd.

    CPC分类号: C07D263/58 A61K31/496

    摘要: It is intended to provide a novel compound, which sustains an ACAT inhibitory activity and a macrophage-selectivity to a certain degree as a practically usable drug and can maintain an excellent oral absorption property and a favorable drug concentration in case of tested in vivo; a process for producing the same; medicinal compositions comprising the same and its intermediate. Namely, 2-[4-[2-(7-trifuoromethylbenzoxazol-2-ylthio)-ethyl]piperazin-1-yl]-N-(2,6-diisopropyl-4-hydroxyphenyl)-acetamide represented by the following formula: salts thereof or solvates of the same; and medicinal compositions comprising the compound represented by the above formula, salts thereof or solvates of the same together with pharmaceutically acceptable carriers.

    摘要翻译: 旨在提供一种新型化合物,其作为实用可用的药物在一定程度上维持ACAT抑制活性和巨噬细胞选择性,并且在体内测试的情况下可以保持优异的口服吸收性和良好的药物浓度; 生产该工艺的方法; 包含其的药物组合物及其中间体。 即,由下式表示的2- [4- [2-(7-三氟甲基苯并恶唑-2-基硫代) - 乙基]哌嗪-1-基] -N-(2,6-二异丙基-4-羟基苯基) 其盐或其溶剂合物; 以及包含由上式表示的化合物,其盐或其溶剂合物以及药学上可接受的载体的药物组合物。